Exagen (XGN) Research & Development (2018 - 2026)

Exagen (XGN) has 9 years of Research & Development data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Research & Development rose 20.95% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 16.48% YoY) and the FY2025 annual result came in at $6.3 million, up 16.35% from the prior year.
• Research & Development fell to $1.6 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $2.7 million in Q4 2022 to a low of $1.1 million in Q1 2024.
• A 5-year average of $1.6 million and a median of $1.5 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development sank 60.16% — and 2024, when it soared 53.9%.
• Tracing XGN's Research & Development over 5 years: stood at $2.7 million in 2022, then slumped by 60.16% to $1.1 million in 2023, then soared by 53.9% to $1.7 million in 2024, then gained by 6.1% to $1.8 million in 2025, then retreated by 11.61% to $1.6 million in 2026.
• The last three Research & Development figures came in at $1.6 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.